Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin

By Stenlöf Kaj   Raz Itamar   Neutel Joel   Ravichandran Shoba   Berglind Niklas   Chen Roland  

Current Medical Research and Opinion, Vol. 26, Iss. 10, 2010-10 ,pp. : 2355-2363

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM

By Perez Alfonso   Zhao Zhen   Jacks Randal   Spanheimer Robert  

Current Medical Research and Opinion, Vol. 25, Iss. 12, 2009-12 ,pp. : 2915-2923

Informa Healthcare

Access to resources Recommend Favorite

Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer

By Boyraz Baris   Sendur Mehmet A.N.   Aksoy Sercan   Babacan Taner   Roach Emir C.   Kizilarslanoglu Muhammet C.   Petekkaya Ibrahim   Altundag Kadri  

Current Medical Research and Opinion, Vol. 29, Iss. 4, 2013-04 ,pp. : 405-414

Informa Healthcare

Access to resources Recommend Favorite

Validation of economic and health outcomes simulation model of type 2 diabetes mellitus (ECHO-T2DM)

By Willis Michael   Asseburg Christian   He Jianming  

Journal of Medical Economics, Vol. 16, Iss. 8, 2013-08 ,pp. : 1007-1021

Informa Healthcare

Access to resources Recommend Favorite

[HDL‐C/apoA‐I]: A multivessel cardiometabolic risk marker in women with T2DM

By  

DIABETES/METABOLISM: RESEARCH AND REVIEWS (ELECT), Vol. 34, Iss. 1, 2018-01 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite